- Oops!Something went wrong.Please try again later.
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe
Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer
INDIANAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the first patient in the European Union (EU) has been dosed in the Phase 3 SPLASH trial (NCT04647526). The SPLASH trial is investigating the use of 177Lu-PNT2002, a PSMA-targeted radioligand, in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC), with entry criteria including a positive PSMA-PET scan with either 68Ga-PSMA-11 or 18F-DCFPyL.
The SPLASH trial began randomization in North America in September 2021, and a total of 37 trial sites across North America and Europe are currently enrolling patients. Site activations in remaining jurisdictions continue to further accelerate trial recruitment. The Company continues to expect to report top line data from SPLASH mid-2023.
“I’m pleased with our team’s consistent execution of the SPLASH trial,” said Dr. Joe McCann, CEO of POINT Biopharma. “In two years, we’ve gone from a pre-IND meeting with the FDA to dosing patients in multiple countries, and I’m proud of our team for realizing this achievement. We remain on track to complete recruitment by the end of this year, and to disclose efficacy and safety data from the 27-patient lead-in in the second half of 2022.”
In February 2022, the Company announced publication of the first data from the SPLASH trial, dosimetry results from the lead-in cohort. The findings presented by Dr. Jean-Mathieu Beauregard concluded that “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied." To provide additional context on interpreting dosimetry, the Company also hosted an investor education event titled “Introduction to Dosimetry for Radiopharmaceuticals” shortly after the release of the data. The 30-minute educational webinar was led by Dr. Ana Kiess, M.D., Ph.D., Assistant Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins Hospital, and provides more context into interpreting dosimetry results. A replay of the webinar and the slides are available to download at https://hub.pointbiopharma.com/dosimetry.
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 and lutetium-177. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/. Information about POINT Biopharma Global Inc.’s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the benefits of the recently completed business combination, as well as statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the outcome of any legal proceedings that may be instituted against POINT following the closing of the business combination, the risk that the business combination disrupts current plans and operations, the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of POINT to grow and manage growth profitably and retain its key employees, the impact of COVID-19 on POINT’s business, the ability to maintain the listing of POINT’s common stock on the NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in POINT's S-1 registration statement filed with the SEC on July 30, 2021. Most of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Chief of Staff
Investor Relations Contact:
Associate Director, Corporate Strategy